Centro Médico Teknon, C/Vilana 12, 08022, Barcelona, Spain,
Med Oral Patol Oral Cir Bucal. 2019 Jul 1;24(4):e416-e424. doi: 10.4317/medoral.22923.
Currently it has been shown that botulinum toxin is effective for a wide variety of medical conditions, and can be applied for therapeutic purposes as cosmetic. In recent years, there has been a growing trend in the use of this drug substance to control the muscular overactivity of bruxism. The objective of this study was the use of botulinum toxin type A (BTX-A) than traditional methods, by conducting a systematic review of randomized clinical trials (RCTs) published in the health sciences literature.
An electronic search was made in the databases of the PubMed, Cochrane Library and Scopus data between March and October 2017, ECA, which will analyze the effect of botulinum toxin in the treatment of bruxism. We included studies of bruxist patients older than 18 years where BTX-A tests were performed on the masseter and / or temporal muscles and the control systems were injections of placebo (saline) or the use of traditional methods for the treatment of bruxism. such as occlusal splints, other medications or cognitive-behavioral therapy.
Of the 68 studies identified, 4 RCTs that fit our inclusion criteria were selected. These studies show that BTX-A injections can reduce the frequency of bruxism episodes, decrease pain levels and maximum occlusal force generated by this pathology, offer superior efficacy in the treatment of bruxism compared to control groups who were treated with placebo or with traditional methods for the treatment of bruxism.
Infiltrations with BTX-A are a safe and effective treatment for patients with bruxism, so its use is justified in daily clinical practice, especially in patients diagnosed with severe bruxism.
目前已经证明,肉毒毒素对于多种医学病症都具有显著疗效,且可作为美容用途应用于治疗。近年来,这种药物在控制磨牙症肌肉过度活动方面的应用呈增长趋势。本研究旨在使用肉毒毒素 A 型(BTX-A)替代传统方法,对已发表在健康科学文献中的随机临床试验(RCT)进行系统回顾。
2017 年 3 月至 10 月,我们在 PubMed、Cochrane 图书馆和 Scopus 数据库中进行了电子检索,并分析了肉毒毒素治疗磨牙症的效果。我们纳入了年龄大于 18 岁的磨牙症患者的研究,这些患者接受了咬肌和/或颞肌的 BTX-A 测试,对照组接受了安慰剂(盐水)注射或磨牙症传统治疗方法(如咬合垫、其他药物或认知行为疗法)。
在确定的 68 项研究中,有 4 项 RCT 符合我们的纳入标准。这些研究表明,BTX-A 注射可以减少磨牙症发作的频率,降低该病症引起的疼痛水平和最大咬合力,与接受安慰剂或传统方法治疗的对照组相比,在磨牙症治疗方面具有更好的疗效。
BTX-A 浸润是治疗磨牙症患者的一种安全有效的方法,因此在日常临床实践中使用是合理的,尤其是在诊断为严重磨牙症的患者中。